Clinical Updates – Medxy AI

Transcutaneous Peripheral Nerve Stimulation for Essential Tremor: Advancements from a 2024 Randomized Clinical Trial and Evolving Evidence

By MedXY 10/21/2025

AI-driven transcutaneous peripheral nerve stimulation (TPNS) shows significant improvements in upper limb function for essential tremor (ET), supporting a promising noninvasive treatment approach with manageable safety profile over 90 days.

Clinical Updates news

Enlarged Perivascular Spaces as Early Neurovascular Biomarkers in Alzheimer Disease: Integrating Serum and MRI Findings from Multicultural Cohorts

By MedXY 10/20/2025

Enlarged perivascular spaces (EPVS) correlate with serum biomarkers of neuroinflammation and amyloid pathology and associate with cognitive impairment, supporting their role as early MRI markers for Alzheimer disease (AD) vascular contributions and pathology.

Clinical Updates news

Neoadjuvant TAR-200 Plus Cetrelimab versus Cetrelimab Monotherapy in Muscle-Invasive Bladder Cancer Ineligible for Cisplatin: Interim Phase 2 Trial Analysis

By MedXY 10/15/2025

Interim results from the phase 2 SunRISe-4 trial demonstrate that neoadjuvant TAR-200 combined with cetrelimab significantly improves pathological complete response rates versus cetrelimab alone in muscle-invasive bladder cancer patients ineligible for cisplatin, with manageable safety.

Clinical Updates Critical Care news Pathology & Lab Medicine Pediatrics Public Health Specialties

Clinical Decision Tool Integrating Decision Tree, Point-of-Care CRP Testing, and Safety Netting to Optimize Antibiotic Use in Acutely Ill Children: Evidence from the ARON Pragmatic Trial and Contextual Literature

By MedXY 10/10/2025

The ARON trial demonstrated that a clinical decision tool combining decision tree, point-of-care CRP testing, and safety-netting advice safely reduces antibiotic prescribing in acutely ill children without delaying recovery or increasing healthcare utilization.

Cardiology Clinical Updates news Specialties

Vericiguat in Chronic Heart Failure with Reduced Ejection Fraction: Insights from the VICTOR Phase 3 Trial

By MedXY 10/10/2025

The VICTOR trial evaluated vericiguat in HFrEF patients without recent worsening, showing no significant reduction in composite cardiovascular death or heart failure hospitalization, but fewer cardiovascular and all-cause deaths with acceptable safety.

Clinical Updates Dermatology news Specialties

Once-Daily Oral Icotrokinra vs Placebo and Deucravacitinib in Moderate-to-Severe Plaque Psoriasis: Insights from ICONIC-ADVANCE 1 & 2 Phase 3 Trials

By MedXY 10/10/2025

ICONIC-ADVANCE 1 & 2 phase 3 trials demonstrate that once-daily oral icotrokinra significantly improves skin clearance with superior efficacy and favorable safety compared to placebo and deucravacitinib in moderate-to-severe plaque psoriasis.

Clinical Updates Gastroenterology Oncology Radiology Specialties

Diagnostic Accuracy of MRI and CT in Evaluating Nonviability of Disappearing Colorectal Liver Metastases: An International Prospective Study

By MedXY 10/10/2025

Combining MRI and CT improves detection of nonviable disappearing colorectal liver metastases but does not reliably confirm nonviability, challenging the management of such lesions post-chemotherapy.

Clinical Updates Gastroenterology General Surgery news

Postoperative Pulmonary Complications in Conventional Laparoscopic vs Robot-Assisted Abdominal Surgery: Incidence, Risk Factors, and Clinical Implications

By MedXY 10/10/2025

This review synthesizes evidence comparing postoperative pulmonary complications (PPCs) between robot-assisted surgery (RAS) and conventional laparoscopic surgery (CLS) in abdominal procedures, highlighting the pivotal role of ventilation duration over surgical approach.

Cardiology Clinical Updates news Specialties

Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia: Advances in Antisense Therapies for Triglyceride Reduction

By MedXY 10/03/2025

Olezarsen, a GalNAc-conjugated antisense oligonucleotide targeting APOC3 mRNA, significantly reduces triglyceride levels in moderate hypertriglyceridemia, offering a promising therapeutic advance with favorable safety in cardiovascular risk patients.

Clinical Updates news Psychiatry Specialties

Balancing Risks and Benefits: Early Antipsychotic Dose Reduction Versus Maintenance After First-Episode Psychosis Remission

By MedXY 10/01/2025

A randomized clinical trial reveals early dose reduction of antipsychotics after first-episode psychosis remission increases short-term relapse risk and lowers quality of life, but may improve long-term functioning over four years.

Clinical Updates Neurology news Pediatrics Specialties

Memantine Shows Promise for Improving Social Impairment in Youths with Autism Spectrum Disorder

By MedXY 10/01/2025

A 12-week randomized clinical trial demonstrates memantine’s efficacy and safety in improving social impairments in youths with ASD, with elevated pgACC glutamate levels serving as a predictive biomarker for treatment response.

Clinical Updates news Oncology Specialties

Evaluating the Addition of Polymeric Micellar Paclitaxel to Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer: Insights from a Phase 3 Randomized Clinical Trial

By MedXY 10/01/2025

A South Korean phase 3 trial found that adding polymeric micellar paclitaxel to gemcitabine and cisplatin did not improve survival for advanced biliary tract cancer, highlighting the challenges of intensified chemotherapy regimens.

Clinical Updates OB/GYN & Women's Health Public Health Specialties

Cost-Effectiveness of Mailed HPV Self-Testing Kits for Cervical Cancer Screening Across Diverse Screening Histories

By MedXY 10/01/2025

Economic evaluation shows direct mailing of HPV self-sampling kits improves cervical cancer screening completion and is cost-effective among varied screening history groups in a US healthcare system, with budget benefits over time.

Clinical Updates news Oncology Specialties

Bridging the Gap: Overcoming Barriers to Timely Melanoma Diagnosis and Treatment in Latino Patients

By MedXY 10/01/2025

This article explores the facilitators and barriers Latino patients face in timely melanoma diagnosis and treatment, highlighting health insurance, linguistic challenges, and patient advocacy as key factors affecting outcomes.

Clinical Updates news Psychiatry Specialties

Heart Rate Variability Biofeedback in Substance Use Disorder: Emerging Evidence from a Randomized Clinical Trial and Contextual Review

By MedXY 10/01/2025

Second-generation heart rate variability biofeedback (HRVB) shows promise in reducing craving, negative affect, and substance use in adults with substance use disorder (SUD), supporting its potential as an adjunctive treatment in early recovery.

Cardiology Clinical Updates Nephrology news Specialties

Sustained Cardiovascular Health in Young Adulthood Significantly Reduces Midlife Cardiovascular and Kidney Risks

By MedXY 10/01/2025

A high cumulative cardiovascular health score from ages 30 to 40 correlates with substantially lower risks of cardiovascular and kidney events in midlife, underscoring the impact of early-life prevention strategies.

Clinical Updates General Surgery news Specialties

Non-β-Lactam Antibiotics, β-Lactam Allergy, and Surgical Site Infections: Implications for Prophylaxis and Stewardship

By MedXY 10/01/2025

This study evaluates how reported β-lactam allergy and choice of prophylactic antibiotics impact surgical site infection rates, revealing non-β-lactam use increases SSI risk while allergy alone does not independently predict infections.

Clinical Updates news

Unraveling the Link Between General Intelligence and Alcohol Use Disorder Risk

By MedXY 10/01/2025

This article reviews emerging evidence on how general intelligence and cognitive performance relate to the risk of alcohol use disorder, integrating large-scale population data, genetic analyses, and the role of educational attainment across national contexts.

Clinical Updates Oncology Specialties

Deciphering the Role of Intratumoral Microbiota in Breast Cancer: Pathogenesis to Precision Therapeutics

By MedXY 09/30/2025

Intratumoral microbiota significantly influence breast cancer development, progression, and therapeutic response. Their diverse composition across subtypes presents diagnostic and prognostic opportunities. Emerging strategies target these microbes to improve treatment efficacy and overcome resistance.

Clinical Updates Oncology

Novel Heparanase Inhibitor LMW-DSS Shows Promise in Preventing Breast Cancer Metastasis by Targeting Migration and Angiogenesis

By MedXY 09/30/2025

Low-molecular-weight dextran sulfate sodium (LMW-DSS), a new heparanase inhibitor, effectively prevents breast cancer metastasis in mice by inhibiting cancer cell migration and angiogenesis, offering a promising therapeutic approach with minimal bleeding risk.